ClinicalTrials.gg
Not yet recruitingNCT07854483Updated Oct 13, 2026

C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy

A Phase 1 interventional study of C-CAR168 in Systemic Sclerosis (SSc), Systemic Sclerosis and Systemic Sclerosis (Scleroderma), sponsored by AbelZeta Inc.. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by AbelZeta Inc. · Phase 1, Interventional, and Treatment

Updated Oct 13, 2026First site in United StatesStudy contact changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 165 studies in Scleroderma, Systemic with a site in United States — 40 open to participants now, 52 under way, 6 of them phase 3. Scleroderma, Systemic · United States.

Planned enrollment
113th of 142
12 · median 34
Started
2027
with 1 other
Phase 1
31 of 165
12 open now
Primary completion
2028-12
later than 37 of 51 live
Registered
162nd of 165
by date

Among the 165 studies in Scleroderma, Systemic with a site in United States, this one is the 113th largest by planned enrollment of the 142 interventional ones that give a count, is one of 2 that started in 2027, is one of 31 in phase 1, reaches primary completion later than 37 of the 51 other live ones, and was the 162nd registered.

Scleroderma, Systemic

613 studies on the registry are indexed under Scleroderma, Systemic; 221 are open to participants now.

Browse Scleroderma, Systemic studies →

Open to participants now

40 of the 165 studies in Scleroderma, Systemic with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 145 Scleroderma, Systemic studies recruiting now, 83 (57%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 165 studies in Scleroderma, Systemic with a site in United States, or all of them as a file.
02

Study summary

This Phase 1b, multicenter, open-label study will evaluate the safety and efficacy of a single infusion of autologous anti-CD20/BCMA chimeric antigen receptor T cells (C-CAR168) following lymphodepleting chemotherapy in participants with refractory Systemic Sclerosis (SSc) who are not responding to standard therapy. Approximately 6-12 participants will undergo leukapheresis, lymphodepletion with fludarabine and cyclophosphamide, and infusion of C-CAR168. Participants will be followed for 24 months (2 years) to evaluate safety, CAR T-cell persistence, pharmacokinetics/pharmacodynamics, biomarkers, and preliminary efficacy results. Long-term safety follow-up for gene therapy-related events will continue for up to 15 years following CAR T-cell infusion.

03

Conditions studied

  • Systemic Sclerosis (SSc)
  • Systemic Sclerosis
  • Systemic Sclerosis (Scleroderma)
  • Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria
  • Systemic Sclerosis Pulmonary
  • Systemic Sclerosis With Lung Involvement

Keywords

  • Autoimmune
  • CAR-T
  • CAR T-cell Therapy
  • Systemic Sclerosis
  • SSc
  • Autoimmune disease
  • CD20
  • BCMA
  • CAR-T Therapy
  • Chimeric Antigen Receptor T cell
  • chimeric antigen receptor T-cell Therapy
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Able to sign and date the Form (ICF).
  2. Female or male, aged 18-70 years (inclusive) with body weight ≥40 kg.
  3. Have a clinical diagnosis of diffuse cutaneous SSc according to the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification.
  4. Disease duration between the onset of the first non-Raynaud's sign/symptom and ICF signing shall be ≤ 6 years.
  5. SSc Disease Activity meet all following criteria:

    1. Modified Rodnan Skin Score (mRSS) ≥15.
    2. Chest High Resolution Computed Tomography (HRCT) shows SSc related ground-glass opacities.
    3. Percent predicted forced vital capacity (ppFVC)\<70% or precent predicted (diffusing capacity of the lungs for carbon monoxide) ppDLco\<70%.
  6. Positivity for at least one SSc-specific autoantibodies:

    1. anti-Scl70 antibody.
    2. anti-RNA polymerase III antibody.
    3. anti-centromere antibody.
    4. anti-Th/To antibody.
    5. and anti-U3RNP antibody.
  7. to at least two prior standard-of-care regimens, including immunosuppressives and/or a biologic note: "Refractory" is defined as receiving each listed drug for ≥6 months with either no response, disease progression after transient remission, or persistent disease progression on treatment.
  8. Ability to taper to protocol allowed doses

Exclusion Criteria:

  1. ppFVC\<45% or ppDLco \<40%.
  2. Severe pulmonary arterial hypertension (PAH) as measured by screening echocardiogram (ECHO), or had documented mean positive airway pressure PAP (mPAP) > 45mmHg on recent right heart catheterization (RHC).

    Note: RHC is not mandatory at screening, however participant with high-risk ECHO findings warrant close clinical vigilance, and participant with mPAP> 45mmHg at baseline shall not proceed with lymphodepletion.

  3. Presence of abnormalities on chest high-resolution computed tomography (HRCT) that are UNRELATED to SSc.
  4. Cutaneous sclerosis that impedes venous access required for leukapheresis, lymphodepletion, C-CAR168 infusion, other study procedures and emergency rescue interventions.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    C-CAR168

    Participants will receive: • Leukapheresis • Fludarabine • Cyclophosphamide • Single intravenous infusion of C-CAR168

    Biological: C-CAR168

Interventions

  • BiologicalC-CAR168

    Autologous anti-CD20/BCMA chimeric antigen receptor T-cell therapy administered as a single intravenous infusion

06

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment-emergent adverse events

    Incidence and severity of treatment-emergent adverse events, serious adverse events, dose-limiting toxicities, CRS, ICANS, adverse events of special interest, and treatment- or procedure-related adverse events.

    Time frame: Through Month 24

Secondary outcomes

  1. Proportion of Participants Achieving Response

    Proportion of participants achieving a response per the revised Composite Response Index for Systemic Sclerosis (r-CRISS)

    Time frame: Through Month 24

  2. Pharmacokinetics of C-CAR168 Utilizing Flow Cytometry

    Characterize T-cell expansion and persistence utilizing flow cytometry

    Time frame: Through Month 24

  3. Pharmacokinetics of C-CAR168 measured by quantitative polymerase chain reaction (qPCR)

    Characterize CAR T-cell expansion and persistence using qPCR

    Time frame: Through Month 24

  4. Proportion of Participants Progressed

    Proportion of participants that progress meeting any of the protocol defined progression criteria

    Time frame: Through Month 24

  5. Time to First Response

    Time to participant meeting first response as defined in the protocol

    Time frame: Through Month 24

  6. Duration of Response (DOR)

    Time of response from first response until progression as defined in the protocol

    Time frame: Through 24 months

07

Study locations

1 site
  • Research Site
    Gilbert, Arizona 85234, United States
08

References and documents

Individual participant data

Plan to share: No — Individual participant data collected during this study will not be made available to other researchers.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2027; primary completion for Dec 2028, 21 months later.

Of 44 phase 1 interventional studies under Scleroderma, Systemic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 60. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2026
First posted
Oct 2, 2026
StartEst.
Mar 2027
Primary completionEst.
Dec 2028
CompletionEst.
Mar 2030
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added — first site in United States
Show site
  • Research Site · Gilbert, United States
Oct 13, 2026
Contact
Study contact changed: k•••@abelzeta.com · •••6081→k•••@abelzeta.com · •••6081; added k•••@abelzeta.com · •••6081. See the current contact
Oct 13, 2026
Title
A Phase 1b Study of C-CAR168 in Participants With Systemic Sclerosis (SSc)→C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy
Oct 13, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 2 updates
  1. Oct 13, 2026
    1 site added — first site in United States
    Show site
    • Research Site · Gilbert, United States
    Contact Study contact changed: k•••@abelzeta.com · •••6081→k•••@abelzeta.com · •••6081; added k•••@abelzeta.com · •••6081. See the current contact
    Title A Phase 1b Study of C-CAR168 in Participants With Systemic Sclerosis (SSc)→C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy
    + 2 other changes: verification date and arm descriptions
  2. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07854483
Lead sponsor
AbelZeta Inc.
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Mar 2027 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Mar 2030 (estimated)
Last update
Oct 13, 2026

Study contacts

Kirstin Liechty, Head of Clinical Operations, PhD
Contact
kirstin.liechty@abelzeta.com
267-566-6081
Yihong Liechty, Head of Clinical Operations, PhD
Contact
kirstin.liechty@abelzeta.com
267-566-6081
Yihong Yao, PhD
study director · AbelZeta Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion